Brookline Capital Initiates Coverage On Oncternal Therapeutics with Buy Rating, Announces Price Target of $16
Brookline Capital Initiates Coverage On Oncternal Therapeutics with Buy Rating, Announces Price Target of $16
Brookline Capital以买入评级启动Oncternal治疗药物的覆盖范围,宣布目标价为16美元
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。